Genetic Testing < Genetic Therapy < Genetic Variation

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 26.
[0-20] [0 - 20][0 - 26][20-25][20-40]

Ident.	Authors (with country if any)	Title
000195 (2016)	Yves Lévy	Gene and Cell Therapies: Inserm at the Heart of Biomedical Revolutions.
000325 (2015)	Romina Aron Badin ; Marta Vadori ; Emanuele Cozzi ; Philippe Hantraye	Translational research for Parkinson׳s disease: The value of pre-clinical primate models.
000470 (2014)	P. Remy	Biotherapies for Parkinson disease.
000504 (2014)	Wai Kin D. Ko ; Marie-Laure Martin-Negrier ; Erwan Bezard ; Alan R. Crossman ; Paula Ravenscroft	RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
000571 (2014)	Maria E. Hernandez ; Jesus D. Rembao ; Daniel Hernandez-Baltazar ; Rosa A. Castillo-Rodriguez ; Victor M. Tellez-Lopez ; Yazmin M. Flores-Martinez ; Carlos E. Orozco-Barrios ; Hector A. Rubio ; Aurora Sánchez-García ; Jose Ayala-Davila ; Martha L. Arango-Rodriguez ; Lenin Pav N ; Teresa Mejia-Castillo ; Patricia Forgez ; Daniel Martinez-Fong	Safety of the intravenous administration of neurotensin-polyplex nanoparticles in BALB/c mice.
000586 (2014)	Frédéric Checler ; Cristine Alves Da Costa	p53 in neurodegenerative diseases and brain cancers.
000591 (2014)	Stéphane Palfi ; Jean Marc Gurruchaga ; G Scott Ralph ; Helene Lepetit ; Sonia Lavisse ; Philip C. Buttery ; Colin Watts ; James Miskin ; Michelle Kelleher ; Sarah Deeley ; Hirokazu Iwamuro ; Jean Pascal Lefaucheur ; Claire Thiriez ; Gilles Fenelon ; Cherry Lucas ; Pierre Brugières ; Inanna Gabriel ; Kou Abhay ; Xavier Drouot ; Naoki Tani ; Aurelie Kas ; Bijan Ghaleh ; Philippe Le Corvoisier ; Patrice Dolphin ; David P. Breen ; Sarah Mason ; Natalie Valle Guzman ; Nicholas D. Mazarakis ; Pippa A. Radcliffe ; Richard Harrop ; Susan M. Kingsman ; Olivier Rascol ; Stuart Naylor ; Roger A. Barker ; Philippe Hantraye ; Philippe Remy ; Pierre Cesaro ; Kyriacos A. Mitrophanous	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.
000621 (2014)	M. Anheim	[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].
000951 (????)	Claire Golé ; Romain Reboul ; Pascale Pisano	[Gene therapy in Parkinson disease: a promising future treatment?].
000A15 (2011)	Patrice P. Denèfle	Introduction to gene therapy: a clinical aftermath.
000B51 (2009)	P. Cesaro ; G. Fenelon ; P. Remy	[Biotherapies and Parkinson's disease].
000B55 (2009)	Béchir Jarraya ; Sabrina Boulet ; G Scott Ralph ; Caroline Jan ; Gilles Bonvento ; Mimoun Azzouz ; James E. Miskin ; Masahiro Shin ; Thierry Delzescaux ; Xavier Drouot ; Anne-Sophie Hérard ; Denise M. Day ; Emmanuel Brouillet ; Susan M. Kingsman ; Philippe Hantraye ; Kyriacos A. Mitrophanous ; Nicholas D. Mazarakis ; Stéphane Palfi	Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.
000D26 (2008)	Grégory Porras ; Erwan Bezard	Preclinical development of gene therapy for Parkinson's disease.
000D73 (2007)	Delphine Cuchet ; Corinne Potel ; Joélle Thomas ; Alberto L. Epstein	HSV-1 amplicon vectors: a promising and versatile tool for gene delivery.
000E01 (2007)	N A Do Thi ; P. Saillour ; L. Ferrero ; T. Paunio ; J. Mallet	Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?
000E87 (2006)	Martine Barkats ; Philippe Horellou ; Philippe Colin ; Stéphanie Millecamps ; Nicole Faucon-Biguet ; Jacques Mallet	1-methyl-4-phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutase.
000E92 (2006)	J F Stoltz ; D. Bensoussan ; V. Decot ; A. Ciree ; P. Netter ; P. Gillet	Cell and tissue engineering and clinical applications: an overview.
000F07 (2006)	Mara Brizard ; Carole Carcenac ; Alexis-Pierre Bemelmans ; Claude Feuerstein ; Jacques Mallet ; Marc Savasta	Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
000F97 (2004)	Pierre Cesaro	The design of clinical trials for cell transplantation into the central nervous system.
001012 (2004)	V. Fraix	[Gene therapy for Parkinson's disease].
001021 (2004)	N A Do Thi ; P. Saillour ; L. Ferrero ; J F Dedieu ; J. Mallet ; T. Paunio	Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i -k "Genetic Therapy" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i  \
                -Sk "Genetic Therapy" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Genetic Therapy
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024